News Channels

27 Oct 2022 Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
26 Oct 2022 eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
26 Oct 2022 Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines
26 Oct 2022 Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
26 Oct 2022 Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication
26 Oct 2022 Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecular Glue Discovery and Rational Design at Targeted Protein Degradation Summit
26 Oct 2022 Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225
26 Oct 2022 Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
26 Oct 2022 Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
26 Oct 2022 RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in liver cancer patients
26 Oct 2022 Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
26 Oct 2022 Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
26 Oct 2022 Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
26 Oct 2022 Gritstone Presents Positive Results from Two Phase 1 CORAL Studies, Providing Further Proof-of-Concept for Self-amplifying mRNA (samRNA) in Infectious Diseases
26 Oct 2022 SK bioscience and CEPI Sign Agreement to Develop mRNA Vaccines
26 Oct 2022 Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)
26 Oct 2022 Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
26 Oct 2022 Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022
26 Oct 2022 Camizestrant significantly improved progression-free survival vs. Faslodex in SERENA-2 Phase II trial in advanced ER-positive breast cancer
26 Oct 2022 Capivasertib plus Faslodex significantly improved progression-free survival vs. Faslodex in CAPItello-291 Phase III trial in advanced HR-positive breast cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up